Src-Mediated Phosphorylation of the Tyrosine Phosphatase PRL-3 Is Required for PRL-3 Promotion of Rho Activation, Motility and Invasion

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Fiordalisi, James J ^a   Dewar, Brian J ^b   Graves, Lee M ^a,b   Madigan, James P ^b   Cox, Adrienne D ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PRL 3 PROTEIN; PROTEIN KINASE FYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHOC GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; COLLAGEN; DRUG COMBINATION; IMMEDIATE EARLY PROTEIN; LAMININ; MATRIGEL; PROTEOGLYCAN; PTP4A3 PROTEIN, MOUSE; RAS PROTEIN; RHOC PROTEIN, MOUSE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; FIBROBLAST; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DRUG COMBINATION; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOPRECIPITATION; LAMININ; MICE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN TYROSINE PHOSPHATASES; PROTEOGLYCANS; RAS PROTEINS; RNA, SMALL INTERFERING; SRC-FAMILY KINASES;

EID: 84877848617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064309     Document Type: Article

References (58)

1. Al-Aidaroos AQ, Zeng Q, (2010) PRL-3 phosphatase and cancer metastasis. J Cell Biochem 111: 1087-1098.
2. Bessette DC, Qiu D, Pallen CJ, (2008) PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 27: 231-252.
3. Rios P, Li X, Kohn M, (2013) Molecular mechanisms of the PRL phosphatases. The FEBS journal 280: 505-524.
4. Fiordalisi JJ, Keller PJ, Cox AD, (2006) PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 66: 3153-3161.
5. Guo K, Li J, Tang JP, Koh V, Gan BQ, et al. (2004) Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer Biol Ther 3: 945-951.
6. Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, et al. (2001) Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun 283: 1061-1068.
7. McParland V, Varsano G, Li X, Thornton J, Baby J, et al. (2011) The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides. Biochemistry 50: 7579-7590.
8. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, et al. (2004) Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 164: 2039-2054.
9. Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, et al. (2008) The metastasis-associated gene Prl-3 Is a p53 target involved in cell-cycle regulation. Mol Cell 30: 303-314.
10. Zheng P, Meng HM, Gao WZ, Chen L, Liu XH, et al. (2011) Snail as a key regulator of PRL-3 gene in colorectal cancer. Cancer biology & therapy 12: 742-749.
11. Xu J, Cao S, Wang L, Xu R, Chen G, et al. (2011) VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. PloS one 6: e27165.
12. Wang H, Vardy LA, Tan CP, Loo JM, Guo K, et al. (2010) PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer cell 18: 52-62.
13. Choi MS, Min SH, Jung H, Lee JD, Lee TH, et al. (2011) The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability. Biochemical and biophysical research communications 406: 305-309.
14. Cirri P, Chiarugi P, Taddei L, Raugei G, Camici G, et al. (1998) Low molecular weight protein-tyrosine phosphatase tyrosine phosphorylation by c-Src during platelet-derived growth factor-induced mitogenesis correlates with its subcellular targeting. J Biol Chem 273: 32522-32527.
15. Tailor P, Gilman J, Williams S, Couture C, Mustelin T, (1997) Regulation of the low molecular weight phosphotyrosine phosphatase by phosphorylation at tyrosines 131 and 132. J Biol Chem 272: 5371-5374.
16. Park S, (2003) The EphA8 receptor phosphorylates and activates low molecular weight phosphotyrosine protein phosphatase in vitro. J Biochem Mol Biol 36: 288-293.
17. Bucciantini M, Chiarugi P, Cirri P, Taddei L, Stefani M, et al. (1999) The low Mr phosphotyrosine protein phosphatase behaves differently when phosphorylated at Tyr131 or Tyr132 by Src kinase. FEBS Lett 456: 73-78.
18. Schwarzer D, Zhang Z, Zheng W, Cole PA, (2006) Negative regulation of a protein tyrosine phosphatase by tyrosine phosphorylation. J Am Chem Soc 128: 4192-4193.
19. Dadke S, Kusari A, Kusari J, (2001) Phosphorylation and activation of protein tyrosine phosphatase (PTP) 1B by insulin receptor. Mol Cell Biochem 221: 147-154.
20. Tao J, Malbon CC, Wang HY, (2001) Insulin stimulates tyrosine phosphorylation and inactivation of protein-tyrosine phosphatase 1B in vivo. J Biol Chem 276: 29520-29525.
21. Kakazu A, Sharma G, Bazan HE, (2008) Association of protein tyrosine phosphatases (PTPs)-1B with c-Met receptor and modulation of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 49: 2927-2935.
22. Zhang Z, Shen K, Lu W, Cole PA, (2003) The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J Biol Chem 278: 4668-4674.
23. Lu W, Gong D, Bar-Sagi D, Cole PA, (2001) Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell 8: 759-769.
24. Mitra S, Beach C, Feng GS, Plattner R, (2008) SHP-2 is a novel target of Abl kinases during cell proliferation. J Cell Sci 121: 3335-3346.
25. Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R, (1994) PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol 14: 3752-3762.
26. Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P, (1999) Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 18: 2459-2471.
27. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, et al. (2002) Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160: 579-584.
28. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, et al. (2009) miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27: 1712-1721.
29. Nakamura Y, Tanaka F, Yoshikawa Y, Mimori K, Inoue H, et al. (2008) PDGF-BB is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 15: 2129-2136.
30. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, et al. (2010) Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806: 122-130.
31. Aleshin A, Finn RS, (2010) SRC: A Century of Science Brought to the Clinic. Neoplasia 12: 599-607.
32. Dietrich KA, Schwarz R, Liska M, Grass S, Menke A, et al. (2009) Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activity. Biol Chem 390: 1063-1077.
33. Narumiya S, Tanji M, Ishizaki T, (2009) Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28: 65-76.
34. Sequeira L, Dubyk CW, Riesenberger TA, Cooper CR, van Golen KL, (2008) Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis. Clin Exp Metastasis 25: 569-579.
35. Guzinska-Ustymowicz K, Pryczynicz A, (2011) PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anti-cancer agents in medicinal chemistry 11: 99-108.
36. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, et al. (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294: 1343-1346.
37. Kim NW, Chu CW, Ahn TS, Kim CJ, Jung DJ, et al. (2011) Correlation between Liver Metastases and the Level of PRL-3 mRNA Expression in Patients with Primary Colorectal Cancer. J Korean Soc Coloproctol 27: 231-236.
38. Mayinuer A, Yasen M, Mogushi K, Obulhasim G, Xieraili M, et al. (2013) Upregulation of Protein Tyrosine Phosphatase Type IVA Member 3 (PTP4A3/PRL-3) is Associated with Tumor Differentiation and a Poor Prognosis in Human Hepatocellular Carcinoma. Ann Surg Oncol 20: 305-317.
39. Tamagawa H, Oshima T, Yoshihara K, Watanabe T, Numata M, et al. (2012) The Expression of the Phosphatase Regenerating Liver 3 Gene is Associated with Outcome in Patients with Colorectal Cancer. Hepatogastroenterology 59.
40. Ustaalioglu BB, Bilici A, Barisik NO, Aliustaoglu M, Vardar FA, et al. (2012) Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer. Clin Transl Oncol 14: 911-922.
41. Jian M, Nan L, Guocheng J, Qingfu Z, Xueshan Q, et al. (2012) Downregulating PRL-3 inhibit migration and invasion of lung cancer cell via RhoA and mDia1. Tumori 98: 370-376.
42. Krndija D, Munzberg C, Maass U, Hafner M, Adler G, et al. (2012) The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration through Arf-activity-dependent stimulation of integrin alpha5 recycling. J Cell Sci 125: 3883-3892.
43. Liang F, Liang J, Wang WQ, Sun JP, Udho E, et al. (2007) PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 282: 5413-5419.
44. Peng L, Xing X, Li W, Qu L, Meng L, et al. (2009) PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol Cancer 8: 110.
45. Zeng Q, Dong JM, Guo K, Li J, Tan HX, et al. (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63: 2716-2722.
46. Qian F, Li YP, Sheng X, Zhang ZC, Song R, et al. (2007) PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol Med 13: 151-159.
47. Zimmerman MW, Homanics GE, Lazo JS, (2013) Targeted Deletion of the Metastasis-Associated Phosphatase Ptp4a3 (PRL-3) Suppresses Murine Colon Cancer. PloS one 8: e58300.
48. Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, et al. (2004) Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J Biol Chem 279: 11882-11889.
49. Jeong DG, Kim SJ, Kim JH, Son JH, Park MR, et al. (2005) Trimeric structure of PRL-1 phosphatase reveals an active enzyme conformation and regulation mechanisms. J Mol Biol 345: 401-413.
50. Sun JP, Wang WQ, Yang H, Liu S, Liang F, et al. (2005) Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry 44: 12009-12021.
51. Brandman O, Meyer T, (2008) Feedback loops shape cellular signals in space and time. Science 322: 390-395.
52. Dunlop EA, Tee AR, (2009) Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal 21: 827-835.
53. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, et al. (2009) (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 106: 4519-4524.
54. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
55. Achiwa H, Lazo JS, (2007) PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res 67: 643-650.
56. Talamonti MS, Roh MS, Curley SA, Gallick GE, (1993) Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60.
57. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE, (1993) Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res 54: 293-298.
58. Zhang S, Yu D, (2012) Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends in pharmacological sciences 33: 122-128.